Drugs / Elismetrep
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT03471130 | Apr → Oct 2018 | — | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03381404 | Dec 2017 → Jan 2018 | — | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02803268 | Jun 2016 → Jan 2017 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02675309 | Feb → Mar 2016 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02536209 | Aug → Nov 2015 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02429102 | Apr → Nov 2015 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06848075 | Mar → Aug 2025 | migraine disorder | Kallyope Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05123196 | Nov 2021 → Nov 2022 | diabetic polyneuropathy | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 2 | NCT03541200 | Apr 2018 → Nov 2019 | — | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03291067 | Oct 2017 → Oct 2018 | premature menopause | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03172598 | Jul 2017 → Aug 2018 | diabetic polyneuropathy | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07816367 | Oct 2026 → Oct 2027 expected | migraine disorder | Kallyope Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07645924 | Jul 2026 → Feb 2027 expected | migraine disorder | Kallyope Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07674654 | Jul 2026 → Jun 2028 expected | migraine disorder | Kallyope Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-06-04 | Kallyope Inc. | Results Kallyope Presents New Data on Novel TRPM8 Channel Blocker Elismetrep for the Acute Treatment for Migraine at the American Headache Society 68th Annual Scientific Meeting kallyope.com ↗
Today, the Company presented results from several clinical and preclinical studies that support the initiation of Phase 3 studies of elismetrep, a novel TRPM8 channel blocker. |
| 2026-04-22 | Kallyope Inc. | Results Kallyope’s Phase 2b Study of Elismetrep, A Novel Approach for Treating Migraine, Presented at the American Academy of Neurology Annual Meeting kallyope.com ↗
Today, the Company presented results from a Phase 2b dose-ranging and proof of concept study of elismetrep, a novel TRPM8 channel blocker and the only agent known to be in late-stage development for the acute treatment of migraine. |
| 2026-03-05 | Kallyope Inc. | Results Kallyope to Present Phase 2b Study Results for Elismetrep for the Acute Treatment of Migraine at the 2026 American Academy of Neurology Annual Meeting kallyope.com ↗
Data validate novel TRPM8 migraine-associated channel blocker (MACB) and demonstrate a clinical profile competitive with leading approved therapeutics for migraine |
| 2025-12-08 | Kallyope Inc. | Results Kallyope Announces Positive Results from Phase 2b Study of Elismetrep for the Acute Treatment of Migraine kallyope.com ↗
In the study, elismetrep delivered a favorable clinical profile through its novel mechanism, supporting its potential as a new therapeutic option for the large number of patients who are suffering from the debilitating effects of migraine. |
All press releases naming this drug 4 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elismetrep | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07645924 ↗ |
| Known as | K-304 | “A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine” NCT06848075 ↗1“Elismetrep (K-304)” NCT07645924 ↗ |
| Known as | MT 8554 | “This is a study to definitively assess the effects of MT 8554, adjusted for placebo, on the change of the QT interval corrected for heart rate (HR) using the Fridericia formula...” NCT03471130 ↗ |
| Action | Inhibit | “Transient receptor potential cation channel subfamily M member 8 inhibitor” CHEMBL3682589 ↗ |
| Modality | Small molecule | — CHEMBL3682589 ↗ |
| Route | Oral | “MT-8554 1mg QD, oral, 12 weeks” NCT03291067 ↗ |
| Target | TRPM8 | “Transient receptor potential cation channel subfamily M member 8 inhibitor” CHEMBL3682589 ↗ |